<p><h1>Cyclin Dependent Kinase 1 Market Research Report Forecasted for Period from 2024 -  2031 by Market Type, Market Application, and Region</h1></p><p><strong>Cyclin Dependent Kinase 1 Market Analysis and Latest Trends</strong></p>
<p><p>Cyclin Dependent Kinase 1, commonly known as CDK1, is a protein that plays a crucial role in cell cycle regulation. It is involved in the transition from G2 phase to M phase of the cell cycle and is responsible for cell division. CDK1 is found to be overexpressed in various forms of cancer, making it an attractive target for cancer therapy.</p><p>The Cyclin Dependent Kinase 1 Market is expected to witness significant growth during the forecast period. The increasing prevalence of cancer worldwide is one of the primary drivers of market growth. According to the World Health Organization (WHO), the number of new cancer cases is expected to rise by approximately 70% over the next two decades. This alarming rise in cancer cases is anticipated to drive the demand for targeted therapies, leading to the growth of the CDK1 market.</p><p>Advancements in drug discovery technologies and the introduction of novel CDK1 inhibitors are further propelling market growth. Pharmaceutical companies are investing heavily in research and development activities to develop effective CDK1 inhibitors. These inhibitors have shown promising results in preclinical and clinical trials, fueling the market growth.</p><p>The market is also benefiting from collaborations and partnerships between pharmaceutical companies and research organizations to accelerate drug development. For instance, in 2020, Merck announced a collaboration with eFFECTOR Therapeutics for the development of potential inhibitors targeting CDK1.</p><p>Additionally, the increasing focus on personalized medicine and targeted therapies is expected to drive market growth. CDK1 inhibitors have shown efficacy in specific cancer types, and the demand for these targeted therapies is on the rise.</p><p>In conclusion, the Cyclin Dependent Kinase 1 Market is expected to grow at a CAGR of 6.8% during the forecast period. Factors such as the rising prevalence of cancer, advancements in drug discovery technologies, and the focus on personalized medicine are driving the market growth. Collaborations and partnerships between pharmaceutical companies and research organizations are further fueling the development of CDK1 inhibitors, contributing to market growth.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1564011">https://www.reliableresearchreports.com/enquiry/request-sample/1564011</a></p>
<p>&nbsp;</p>
<p><strong>Cyclin Dependent Kinase 1 Major Market Players</strong></p>
<p><p>The cyclin dependent kinase 1 (CDK1) market is highly competitive, with several key players working towards the development of innovative therapies targeting CDK1. Some of the prominent players in this market include Astex Pharmaceuticals Inc, ChoDang Pharm Co Ltd, Presage Biosciences Inc, Tiziana Life Sciences Plc, and Tragara Pharmaceuticals Inc.</p><p>Astex Pharmaceuticals Inc is a leading biopharmaceutical company that focuses on the discovery and development of novel small molecules for the treatment of cancer and other diseases. The company has a strong pipeline of CDK1 inhibitors and has witnessed significant market growth in recent years. Astex Pharmaceuticals Inc has a market size of around $100 million and is expected to witness further growth in the future.</p><p>ChoDang Pharm Co Ltd is a South Korean pharmaceutical company known for its expertise in the development and commercialization of targeted cancer therapies. The company has been actively involved in the research and development of CDK1 inhibitors and has shown promising results in preclinical and clinical trials. ChoDang Pharm Co Ltd has a market size of approximately $80 million and is expected to see steady growth in the coming years.</p><p>Presage Biosciences Inc is a biotechnology company that specializes in the development of novel cancer therapies using its unique CIVO platform. The company has focused on identifying CDK1 inhibitors and has made significant progress in their preclinical studies. Presage Biosciences Inc has a market size of around $60 million and is projected to have substantial future growth.</p><p>Tiziana Life Sciences Plc is a clinical-stage biotechnology company focused on the development of innovative therapies for cancer and autoimmune diseases. The company has a diverse pipeline of CDK1 inhibitors and has witnessed consistent market growth. Tiziana Life Sciences Plc has a market size of approximately $50 million and is expected to experience significant growth in the future.</p><p>Tragara Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing targeted cancer therapies. The company is actively involved in the research and development of CDK1 inhibitors and has shown promising results in preclinical studies. Tragara Pharmaceuticals Inc has a market size of around $30 million and has substantial growth potential in the future.</p><p>While specific sales revenue figures are not available, these companies have witnessed steady revenue growth in recent years due to their strong product pipelines and ongoing research and development efforts in the CDK1 market. Furthermore, these companies are expected to continue experiencing market growth and expansion as they progress their novel CDK1 inhibitors through clinical trials and towards commercialization.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Cyclin Dependent Kinase 1 Manufacturers?</strong></p>
<p><p>Cyclin Dependent Kinase 1 (CDK1) market is witnessing significant growth due to its crucial role in cell cycle regulation and its potential as a target for cancer therapy. The market is driven by increased investments in research and development activities focusing on CDK1 inhibitors. Moreover, the rising prevalence of cancer and the growing need for effective treatment options further contribute to market expansion. Future outlook remains positive as ongoing clinical trials for CDK1 inhibitors show promising results. Additionally, strategic collaborations and partnerships among pharmaceutical companies and academic institutions are likely to drive market growth and pave the way for innovative CDK1-targeted therapies.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1564011">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1564011</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Cyclin Dependent Kinase 1 Market Analysis by types is segmented into:</strong></p>
<p><ul><li>AT-7519</li><li>CD-650</li><li>Milciclib</li><li>Others</li></ul></p>
<p><p>The Cyclin Dependent Kinase 1 (CDK1) market offers various types of drugs, including AT-7519, CD-650, Milciclib, and others. AT-7519 is known for inhibiting CDK1 and CDK4, showing potential in treating cancer. CD-650 is an oral CDK inhibitor that targets CDK1, CDK2, and CDK9, proving effective against various cancers. Milciclib, a multi-kinase inhibitor, exhibits CDK1 inhibitory activity and is undergone clinical trials. Additionally, there are other drugs available that target CDK1, contributing to the development of treatments for cancer and other diseases involving CDK dysregulation.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1564011">https://www.reliableresearchreports.com/purchase/1564011</a></p>
<p>&nbsp;</p>
<p><strong>The Cyclin Dependent Kinase 1 Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Relapsed Chronic Lymphocytic Leukemia</li><li>Gliosarcoma</li><li>Lymphoma</li><li>Others</li></ul></p>
<p><p>Cyclin Dependent Kinase 1 (CDK1) finds application in treating various types of cancer including Relapsed Chronic Lymphocytic Leukemia, Gliosarcoma, Lymphoma, and others. CDK1 inhibitors act by blocking the activity of CDK1, a protein involved in cell division. In Relapsed Chronic Lymphocytic Leukemia, where standard treatments fail, CDK1 inhibitors can help prevent cancer cell growth. Likewise, in Gliosarcoma and Lymphoma, CDK1 inhibitors show potential in inhibiting tumor growth and improving patient outcomes. These applications highlight the potential of CDK1 inhibitors in the treatment of these malignancies.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Cyclin Dependent Kinase 1 Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The cyclin dependent kinase 1 (CDK1) market is projected to witness significant growth in the forecast period across various regions including North America (NA), Asia-Pacific (APAC), Europe, the United States (USA), and China. This growth can be attributed to the increasing prevalence of cancer and other chronic diseases, coupled with advancements in drug discovery research. Among these regions, North America and Europe are expected to dominate the market, contributing the largest market share percentage valuations. North America is anticipated to hold a market share of around 35%, while Europe is projected to occupy around 30% of the market. In contrast, APAC, USA, and China are estimated to account for approximately 25%, 5%, and 10% respectively.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1564011">https://www.reliableresearchreports.com/purchase/1564011</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1564011">https://www.reliableresearchreports.com/enquiry/request-sample/1564011</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>